Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations

GlobeNewswire May 3, 2017

Investor Calendar Invites You to the Amarin First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, May 3, 2017

Accesswire May 2, 2017

Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017

GlobeNewswire April 25, 2017

Drug Makers Stocks Under Scanner -- Teva Pharma, Endo, Ionis Pharma, and Amarin

PR Newswire March 27, 2017

Watch These 8 Huge Call Purchases In Wednesday Trade

Benzinga.com  March 22, 2017

Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study

GlobeNewswire March 16, 2017

Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology

GlobeNewswire March 15, 2017

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  February 28, 2017

Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations

GlobeNewswire February 28, 2017

Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017

GlobeNewswire February 22, 2017

Drug Makers Stocks Under Scanner -- Teva Pharma, Endo, Ionis Pharma, and Amarin

PR Newswire February 14, 2017

Amarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference

GlobeNewswire February 9, 2017

The Biotech Market Grows as Demand for New Therapeutics Increases

PR Newswire February 6, 2017

Watch These 8 Huge Call Purchases In Thursday Trade

Benzinga.com  January 26, 2017

Amarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes

GlobeNewswire January 20, 2017

Drug Makers Stocks on Investors' Radar -- Teva Pharma, Endo, Amarin, and Ionis Pharma

PR Newswire January 6, 2017

Amarin Provides Preliminary 2016 Results and 2017 Outlook

GlobeNewswire January 5, 2017

Biotech Stocks Forge Ahead With Confidence on This Week's Healthy Biotech Rally

PR Newswire November 17, 2016

Pure EPA Vascepa® (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Parameters in Statin-Treated Women with Persistent High Triglycerides

GlobeNewswire November 14, 2016

Amarin to Present at the Jefferies 2016 London Healthcare Conference

GlobeNewswire November 11, 2016